Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry.
cancer
pulmonary embolism
registry
thrombosis
venous thromboembolism
Journal
Japanese journal of clinical oncology
ISSN: 1465-3621
Titre abrégé: Jpn J Clin Oncol
Pays: England
ID NLM: 0313225
Informations de publication
Date de publication:
22 Oct 2020
22 Oct 2020
Historique:
received:
14
04
2020
accepted:
26
06
2020
pubmed:
28
7
2020
medline:
13
11
2020
entrez:
28
7
2020
Statut:
ppublish
Résumé
The Cancer-VTE Registry evaluates the occurrence and management of venous thromboembolism in Japanese participants with major solid tumors. Using Registry data, we evaluated the frequency of concurrent venous thromboembolism in cancer patients prior to treatment initiation by cancer type. The Cancer-VTE Registry is an ongoing (March 2017-September 2020) prospective cohort study using a nationwide, multicentre clinical registry. Participants aged ≥20 years with colorectal, lung, stomach, pancreatic, breast or gynecologic cancer, confirmed staging, ≥6 months life expectancy post-registration and who had undergone venous thromboembolism screening were managed with routine clinical care. Venous thromboembolism frequency at registration was evaluated. Of 9735 participants, 571 (5.9%) had venous thromboembolism at baseline, including asymptomatic [5.5% (n = 540)] and symptomatic venous thromboembolism [0.3% (n = 31)]. Most participants with venous thromboembolism (n = 506, 5.2%) had deep vein thrombosis only; 65 (0.7%) had pulmonary embolism with/without deep vein thrombosis. The prevalence of distal and proximal deep vein thrombosis was 4.8% (n = 466) and 0.9% (n = 83), respectively. The highest prevalence of venous thromboembolism was for pancreatic cancer (8.5%) and the lowest for breast cancer (2.0%). Venous thromboembolism prevalence increased as cancer stage advanced. Although there was a marked difference in venous thromboembolism by cancer type, the data suggest that cancer stage is an important risk factor for venous thromboembolism. Thus, metastasis seems a critical risk factor for venous thromboembolism. This is the first demonstration of venous thromboembolism prevalence and risk factors in Japanese cancer patients prior to treatment. UMIN000024942.
Sections du résumé
BACKGROUND
BACKGROUND
The Cancer-VTE Registry evaluates the occurrence and management of venous thromboembolism in Japanese participants with major solid tumors. Using Registry data, we evaluated the frequency of concurrent venous thromboembolism in cancer patients prior to treatment initiation by cancer type.
METHODS
METHODS
The Cancer-VTE Registry is an ongoing (March 2017-September 2020) prospective cohort study using a nationwide, multicentre clinical registry. Participants aged ≥20 years with colorectal, lung, stomach, pancreatic, breast or gynecologic cancer, confirmed staging, ≥6 months life expectancy post-registration and who had undergone venous thromboembolism screening were managed with routine clinical care. Venous thromboembolism frequency at registration was evaluated.
RESULTS
RESULTS
Of 9735 participants, 571 (5.9%) had venous thromboembolism at baseline, including asymptomatic [5.5% (n = 540)] and symptomatic venous thromboembolism [0.3% (n = 31)]. Most participants with venous thromboembolism (n = 506, 5.2%) had deep vein thrombosis only; 65 (0.7%) had pulmonary embolism with/without deep vein thrombosis. The prevalence of distal and proximal deep vein thrombosis was 4.8% (n = 466) and 0.9% (n = 83), respectively. The highest prevalence of venous thromboembolism was for pancreatic cancer (8.5%) and the lowest for breast cancer (2.0%). Venous thromboembolism prevalence increased as cancer stage advanced.
CONCLUSIONS
CONCLUSIONS
Although there was a marked difference in venous thromboembolism by cancer type, the data suggest that cancer stage is an important risk factor for venous thromboembolism. Thus, metastasis seems a critical risk factor for venous thromboembolism. This is the first demonstration of venous thromboembolism prevalence and risk factors in Japanese cancer patients prior to treatment.
TRIAL REGISTRATION
BACKGROUND
UMIN000024942.
Identifiants
pubmed: 32715307
pii: 5876093
doi: 10.1093/jjco/hyaa112
pmc: PMC7579341
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1246-1253Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):39-46
pubmed: 29257737
Circ J. 2011;75(5):1258-81
pubmed: 21441695
JAMA. 2005 Feb 9;293(6):715-22
pubmed: 15701913
Blood. 2017 Sep 28;130(13):1499-1506
pubmed: 28807983
Int J Hematol. 2008 Apr;87(3):250-5
pubmed: 18283526
Jpn J Clin Oncol. 2016 Mar;46(3):204-8
pubmed: 26546690
Hepatobiliary Surg Nutr. 2015 Oct;4(5):325-35
pubmed: 26605280
Blood. 2013 Sep 5;122(10):1712-23
pubmed: 23908465
Blood Coagul Fibrinolysis. 2015 Jan;26(1):13-31
pubmed: 25202884
Eur Respir Rev. 2019 Mar 27;28(151):
pubmed: 30918022
Crit Rev Oncol Hematol. 2017 Oct;118:79-83
pubmed: 28917273
Thromb Haemost. 2017 Jan 26;117(2):219-230
pubmed: 27882374
Circ J. 2019 Oct 25;83(11):2191-2202
pubmed: 31534064
Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S111-22
pubmed: 26433667
Thromb Res. 2010 Jun;125(6):490-3
pubmed: 20097409
J Thromb Haemost. 2017 Aug;15(8):1567-1575
pubmed: 28585779
Thromb Haemost. 2010 Feb;103(2):338-43
pubmed: 20024496
J Med Ultrason (2001). 2008 Mar;35(1):33-6
pubmed: 27278564
N Engl J Med. 2000 Dec 21;343(25):1846-50
pubmed: 11117976
Arch Intern Med. 2000 Mar 27;160(6):809-15
pubmed: 10737280
Blood Coagul Fibrinolysis. 2011 Mar;22(2):86-91
pubmed: 21245746
BMJ Open. 2018 May 30;8(5):e018910
pubmed: 29848769
Support Care Cancer. 2016 Oct;24(10):4105-12
pubmed: 27146390
Eur J Cancer. 2013 Apr;49(6):1404-13
pubmed: 23146958
PLoS Med. 2012;9(7):e1001275
pubmed: 22859911
Br J Cancer. 2018 Apr;118(8):1056-1061
pubmed: 29588512